Lib Therapeutics Appoints David Cory As Chief Executive Officer As Lead Clinical Programs Achieve Phase 3 Completion
Lib Therapeutics Appoints David Cory As Chief Executive Officer As Lead Clinical Programs Achieve Phase 3 Completion
09/11/23, 12:01 PM
Location
cincinnatiIndustry
biotechnology
LIB Therapeutics Inc. , a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of cardiovascular disease , today announced that the Board of Directors has appointed David Cory as Chief Executive Officer and a member of the Board of Directors, effective immediately. Evan Stein, MD, PhD, who has served as the CEO since co-founding LIB in 2015, will continue in a full-time operational role as Chief Operating Officer and Chief Scientific Officer.
Company Info
Location
cincinnati, ohio, united states
Additional Info
LIB Therapeutics is a privately held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients with cardiovascular disease, and the 30 million with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents.